FAQ: Quantum BioPharma's Appointment of Dr. Jack Antel as Clinical Advisor for MS Program
Summary
What is the main announcement in this content?
Quantum BioPharma has appointed Dr. Jack Antel, a world-renowned multiple sclerosis expert and Professor of Neurology at McGill University, as clinical advisor to support the development of their investigational drug Lucid-MS.
Who is Dr. Jack Antel and why is his appointment significant?
Dr. Jack Antel is a world-renowned MS expert, Professor of Neurology at McGill University, and recipient of the National Multiple Sclerosis Society and American Academy of Neurology’s Dystel Award with over 450 published articles, making him highly qualified to guide the design of efficacy trials for Lucid-MS.
What is Lucid-MS and what does it treat?
Lucid-MS is Quantum BioPharma’s patented investigational drug designed to inhibit demyelination in multiple sclerosis, and it has been shown to prevent and reverse myelin degradation in preclinical models.
What stage of development is Lucid-MS currently in?
Quantum BioPharma is advancing Lucid-MS into Phase 2 studies, with Dr. Antel joining to guide the design of efficacy trials.
Who else serves as a clinical advisor for Quantum BioPharma’s MS program?
Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, continues to serve as clinical advisor alongside the newly appointed Dr. Antel.
What other areas does Quantum BioPharma focus on besides MS treatments?
Quantum BioPharma is dedicated to building a portfolio for treating challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development.
What is Quantum BioPharma’s relationship with Unbuzzd Wellness Inc.?
Quantum BioPharma retains 20.11% ownership of Unbuzzd Wellness Inc. and receives royalty payments of 7% of sales from unbuzzd™ until payments total $250 million, after which the royalty drops to 3% in perpetuity.
Where can investors find the latest news and updates about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/
What is Quantum BioPharma’s corporate structure and subsidiaries?
Quantum BioPharma operates through wholly owned subsidiaries including Lucid Psycheceuticals Inc. (focused on Lucid-MS research) and FSD Strategic Investments Inc. (managing strategic investments in loans secured by property).
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 240489